As the global incidence of diabetes and associated treatment costs increase, continuous glucose monitors (CGMs) are recognised as a valuable tool for patient self-monitoring. The source article frames CGMs as instruments that can support improved self-management but notes a market currently dominated by a small number of well-known brands. That market concentration, combined with prescriber and system-level practices within the United Kingdom, can limit adoption of potentially more cost-effective alternatives.
The roundtable contributors emphasise the need to consider both clinical benefit and procurement costs when expanding CGM access across the NHS. The article connects more efficient device selection and prescribing practices with potential reductions in overall healthcare expenditure, while also aiming to preserve or improve patient outcomes.
An expert roundtable convened to evaluate barriers and propose solutions to more efficient CGM use within the UK. Participants represented clinicians and diabetes specialist nurses working in NHS trusts; affiliations listed in the source include multiple consultant physicians, diabetologists and nurse consultants across English NHS organisations. The group identified system-level and practice-level issues that constrain access to a broader range of CGM devices and limit uptake beyond populations such as people with type 1 diabetes, where CGM use is more established.
The panel identified several challenges that reduce the efficiency of CGM procurement and prescribing in the NHS. Key barriers reported in the source include:
The source notes that most CGM adoption has concentrated in populations with type 1 diabetes; this focus may reduce exploration of cost-effective options or tailored prescribing for broader patient groups.
To address identified barriers, the roundtable recommended moving toward more individualised prescribing of CGMs. Examples cited in the source include the provision of accessible readers for elderly patients who may have difficulty with smartphone-based systems. The emphasis is on matching device features and user interfaces to the needs, abilities and preferences of individual patients rather than using a one-size-fits-all approach driven by a narrow set of brands.
The panel also suggested that widening consideration of alternative devices—particularly those that may offer comparable clinical benefits at lower cost—could improve value for the NHS. The source does not provide comparative clinical data or a list of specific devices for procurement; it focuses on the principle of tailoring prescriptions and considering cost-effectiveness during procurement decisions.
Streamlining how CGM data are integrated into health records was highlighted as an important facilitator of efficient care. The roundtable recommended more effective incorporation of CGM outputs into electronic health records to reduce the administrative workload for clinicians and support remote monitoring pathways. Improved data flow could help HCPs manage patients more proactively and lower time spent on manual data handling, according to the source.
These workflow improvements were positioned as enabling greater use of remote monitoring models and supporting patient self-management, while also reducing the time and cost burden on diabetes services.
The panel underscored the importance of expanding education for both HCPs and patients. Reported gaps include insufficient training on device selection, initiation, and troubleshooting for clinicians, and inadequate patient education that would allow users to benefit fully from CGM technology.
Recommendations included targeted HCP training programs to improve confidence in prescribing and managing a broader range of CGM devices, along with patient-facing education resources to support device use, interpretation of data and self-management. The source does not describe specific curricula or training delivery methods; it records the roundtable’s call for enhanced and broader education initiatives.
The authors argue that combining individualised CGM prescription with improved prescribing workflows and enhanced training could both reduce NHS costs and improve diabetes care in the UK. The source frames these changes as likely to lower administration burden, increase patient self-management, and enable more cost-conscious procurement decisions. The article does not present primary economic analyses or quantitative estimates of cost savings; it reports the expert group’s conclusions and rationale.
The article includes a conflict of interest statement: the piece was sponsored by AgaMatrix, and one author (Iain Cranston) has received consultation fees from AgaMatrix. All other authors declared no conflicts. The source does not provide detailed comparative device outcomes, nor specific implementation pathways or quantified cost-benefit analyses; where such details are missing, they are not reported in the source.
Overall, the roundtable promotes policies that prioritise individualised prescribing, broader HCP and patient education, and better CGM data integration into clinical workflows as strategies to improve value and access to CGM technologies across the NHS. Implementation specifics and device-level comparative data were not included in the source article.